A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Cisplatin Combination Expansion:
Arm 1:Patients with TNBC with no prior cytotoxic chemotherapy therapy in the metastatic setting; Arm 2: Patients with TNBC and one or two prior cytotoxic therapies in the metastatic setting.
Arm A: castrate resistant prostate cancer, advanced breast cancer, or non-small cell lunch cancer that are candidates for treatment with a docetaxel-based combination.
Arm B: Urothelial transitional cell cancer, triple negative breast cancer, ovarian cancer or non small cell lunch cancer that are candidates for a cisplatin-based combination.
Arm C: Her2+ breast cancer refractory to prior herceptin or lapatinib, her2+ esophagal-gastric cancer, head and neck squamous cell cancer, or non small cell lunch cancer that are candidates for treatment with a dacomitinib-based combination.
Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not available.
Eastern Cooperative Oncology Group \[ECOG\] performance must be 0 or 1.
Adequate bone marrow, renal and liver function.
You may not be if
Prior therapy for Cisplatin Combination Expansion:
* Prior platinum (carboplatin or cisplatin) in either the adjuvant or metastatic setting;
* Prior radiation to \>25% bone marrow as estimated by the Investigator.
Patients with known symptomatic brain metastases.
Chemotherapy, radiotherapy, biologics or investigational agent within 4 weeks of the lead-in dose.
Major surgery within 4 weeks of the baseline disease assessments.
\>2 prior regimens containing cytotoxic chemotherapy in the metastatic setting.
Active bacterial, fungal or viral infection.
Uncontrolled or significant cardiovascular disease.
Clareo Health | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
